Trevor Allred
Stock Analyst at Oppenheimer
(4.90)
# 239
Out of 4,531 analysts
42
Total ratings
89.7%
Success rate
91.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $157.24 | +33.55% | 7 | May 21, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $105.60 | - | 7 | May 11, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $81.38 | - | 10 | May 11, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $27 → $14 | $16.93 | -19.26% | 2 | Mar 5, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $21.71 | +61.22% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $250 → $275 | $303.39 | -9.36% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintained: Buy | $38 → $80 | $62.92 | +27.15% | 4 | Nov 7, 2025 |
Palvella Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $210
Current: $157.24
Upside: +33.55%
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $105.60
Upside: -
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $81.38
Upside: -
Theravance Biopharma
Mar 5, 2026
Downgraded: Hold
Price Target: $27 → $14
Current: $16.93
Upside: -19.26%
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $21.71
Upside: +61.22%
Ligand Pharmaceuticals
Nov 7, 2025
Maintained: Buy
Price Target: $250 → $275
Current: $303.39
Upside: -9.36%
MBX Biosciences
Nov 7, 2025
Maintained: Buy
Price Target: $38 → $80
Current: $62.92
Upside: +27.15%